SECOND AMENDMENT TO OPTION AND LICENSE AGREEMENTOption and License Agreement • February 27th, 2023 • Xencor Inc • Pharmaceutical preparations
This SECOND AMENDMENT TO OPTION AND LICENSE AGREEMENT (this “Second Amendment”) is entered into as of November 28, 2022, by and between Alexion Pharma International Operations Limited (as successor to Alexion Pharmaceuticals, Inc.), a limited company under Irish law having a principal place of business at College Business & Technology Park, Blanchardstown, Dublin, 15, Ireland (“Alexion”), and Xencor, Inc., a Delaware corporation having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016 (“Xencor”). Alexion and Xencor may each be referred to herein, individually, as a “Party” or, collectively, as the “Parties.”
SIXTH AMENDMENT TO LEASELease • February 27th, 2023 • Xencor Inc • Pharmaceutical preparations
This SIXTH AMENDMENT TO LEASE (this “Amendment”) is made and effective as of October 18, 2022 (the “Effective Date”) by and between 111 LEMON INVESTORS LLC, a California limited liability company successor-in-interest to BF Monrovia, LLC, a California limited liability company (“Landlord”) and XENCOR, INC., a Delaware corporation successor-in-interest to Xencor, Inc., a California corporation (“Tenant”).
FIRST AMENDMENT TO OPTION AND LICENSE AGREEMENTOption and License Agreement • February 27th, 2023 • Xencor Inc • Pharmaceutical preparations
Amendment") is entered into as of June 14 , 2019 , by and between Alexion Pharma Holding (as successor to Alexion Pharmaceuticals, Inc.), an unlimited liability company incorporated under the laws of Ireland and having its principal place of business in Hamilton, Bermuda ("Alexion"), and Xencor, Inc., a Delaware corporation having a principal place of business at I 11 West Lemon Avenue, Monrovia,
